A Phase II trial of SNB-101(as SN-38) in Patients With Advanced Solid Tumors
Latest Information Update: 14 May 2024
At a glance
- Drugs SNB 101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 10 May 2024 According to a SN BioScience media release, IND for phase 2 has been approved in Korea.
- 21 Jul 2023 New trial record
- 20 Jul 2023 According to a SN BioScience media release, IND application for this trial has been field in Korea.